What's Happening

You are here

We will like to share with you the following article by HSA:
(Click the title of the article to read more)

HSA would also like to update healthcare professionals on the conditional approval of remdesivir (Veklury®) for COVID-19, the temporary suspension of sales of EsmyaTM (ulipristal acetate) 5 mg, safety information associated with the use of tofacitinib and ondansetron; and a case study of a drug-induced kidney injury adverse event. 

The news bulletin is posted on the MOH Health Professional Portal and HSA’s website.

  1. Adverse Drug Reaction News; Sep 2020 Vol.22 No.2